A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)

Annals of Oncology

Volumn 26, Issue 8, 2015, Pages 1741-1748

  Ramalingam, Suresh S ^a   Goss, G ^b   Rosell, R ^c   Schmid Bindert, G ^d   Zaric, B ^e   Andric, Z ^f   Bondarenko, I ^g   Komov, D ^h   Ceric, T ⁱ   Khuri, F ^a   Samarzija, M ^j   Felip, E ^k   Ciuleanu, T ^l   Hirsh, V ^m   Wehler, T ⁿ   Spicer, J ^o   Salgia, R ^p   Shapiro, G ^q   Sheldon, E ^r   Teofilovici, F ^r   Vukovic, V ^r   Fennell, D ^s   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF NOVI SAD   (Serbia)

^f Medical Center Bezanijska Kosa   (Serbia)

^g Municipal Clinical Hospital 4   (Ukraine)

^h INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

ⁱ UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^j UNIVERSITY OF ZAGREB   (Croatia)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^m MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

ⁿ JOHANNES GUTENBERG UNIVERSITY   (Germany)

^o KING'S COLLEGE LONDON   (United Kingdom)

^p UNIVERSITY OF CHICAGO   (United States)

^q DANA FARBER CANCER INSTITUTE   (United States)

^r Synta Pharmaceuticals Corp   (United States)

^s UNIVERSITY OF LEICESTER   (United Kingdom)

more..

Author keywords

Adenocarcinoma; Advanced NSCLC; Docetaxel; Ganetespib; HSP90 inhibitor

Indexed keywords

DOCETAXEL; GANETESPIB; HEAT SHOCK PROTEIN 90 INHIBITOR; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90; KRAS PROTEIN, HUMAN; PROTEIN P21; TAXOID; TRIAZOLE DERIVATIVE;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; HEMOPTYSIS; HUMAN; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; TACHYCARDIA; VISUAL IMPAIRMENT; VOMITING; ADENOCARCINOMA; AGED; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS P21(RAS); TAXOIDS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84941614654     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv220     Document Type: Article

References (14)

1. Xiang L, Gilkes DM, Chaturvedi P et al. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. J Mol Med (Berl) 2014; 92: 151-164.
2. Goldman JW, Raju RN, Gordon GA et al. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 2013; 13: 152.
3. Socinski MA, Goldman J, El-Hariry I et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced nonsmall cell lung cancer. Clin Cancer Res 2013; 19: 3068-3077.
4. Jhaveri K, Chandarlapaty S, Lake D et al. A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer 2014; 14: 154-160.
5. Proia DA, Sang J, He S et al. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs 2012; 30: 2201-2209.
6. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ et al. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 2009; 9: 1084-1101.
7. Koukourakis MI, Giatromanolaki A, Sivridis E et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 2003; 89: 877-885.
8. Rademakers SE, Lok J, van der Kogel AJ et al. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 2011; 11: 167.
9. Wang H, Zhao L, Zhu LT et al. Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1alpha and glycolysis, by inhibiting PI3K/Akt signaling pathway. Mol Carcinog 2014; 53(Suppl 1): E107-E118.
10. Liang Y, Zheng T, Song R et al. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1alpha inhibition in hepatocellular carcinoma. Hepatology 2013; 57: 1847-1857.
11. Nagaraju GP, Park W, Wen J et al. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1alpha and STAT-3. Angiogenesis 2013; 16: 903-917.
12. Paraiso KH, Haarberg HE, Wood E et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 2012; 18: 2502-2514.
13. Caldas-Lopes E, Cerchietti L, Ahn JH et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA 2009; 106: 8368-8373.
14. Kauh JS, Harvey RD, Owonikoko TK et al. A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies. J Clin Oncol 2012; 30: abstr 3094.